Assuntos
Agonistas alfa-Adrenérgicos/uso terapêutico , Obstrução das Vias Respiratórias/tratamento farmacológico , Crupe/tratamento farmacológico , Serviços Médicos de Emergência , Auxiliares de Emergência , Epiglotite/tratamento farmacológico , Epinefrina/uso terapêutico , Traqueíte/tratamento farmacológico , Adolescente , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Obstrução das Vias Respiratórias/diagnóstico , Albuterol/uso terapêutico , Criança , Pré-Escolar , Estudos de Coortes , Crupe/diagnóstico , Epiglotite/diagnóstico , Feminino , Humanos , Lactente , Masculino , Estudos Retrospectivos , Traqueíte/diagnóstico , Falha de TratamentoRESUMO
PURPOSE OF REVIEW: The present review draws our attention to ventilator-associated tracheobronchitis (VAT) as a distinct clinical entity that has been associated with progression to ventilator-associated pneumonia (VAP) and worse patient outcomes. In contrast to VAP, which has been extensively investigated for over the past 30 years, most VAT studies have been conducted in the past decade. There are ample data which demonstrate that VAT may progress to VAP, have more ventilator days, and have longer ICU stay that may translate into higher healthcare costs. RECENT FINDINGS: The article focuses on the diagnostic criteria for VAT, causative agents, and studies analyzing associations between VAT and patient outcomes in relation to early, appropriate intravenous, and/or aerosolized antibiotic therapy. Aerosolized antibiotic treatment delivered by improved device technology is a novel approach that has proved to be effective for the treatment and eradication of multidrug-resistant bacterial pathogens. Aerosolized antibiotics are effective in decreasing the use of systemic antibiotics, reducing bacterial resistance, and may also facilitate clinical resolution of infection. SUMMARY: Evidence presented in this review supports treatment of VAT with early and appropriate antibiotic therapy as a standard of care to reduce VAP, ventilator days, and duration of ICU stay in high-risk patient population.
Assuntos
Antibacterianos/uso terapêutico , Bronquite/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Traqueíte/tratamento farmacológico , Bronquite/diagnóstico , Bronquite/economia , Bronquite/patologia , Humanos , Morbidade , Pneumonia Associada à Ventilação Mecânica/diagnóstico , Pneumonia Associada à Ventilação Mecânica/economia , Pneumonia Associada à Ventilação Mecânica/patologia , Traqueíte/diagnóstico , Traqueíte/economia , Traqueíte/patologiaAssuntos
Anti-Inflamatórios/uso terapêutico , Bronquite/complicações , Tosse/etiologia , Prednisona/uso terapêutico , Traqueíte/complicações , Bronquite/tratamento farmacológico , Bronquite/virologia , Doença Crônica , Tosse/tratamento farmacológico , Diagnóstico Diferencial , Humanos , Traqueíte/tratamento farmacológico , Traqueíte/virologiaRESUMO
Adult, professionally active patients with acute purulent tracheobronchitis were treated with azithromycin (3 or 5 days; n = 62) or clarithromycin (7 to 10 days; n = 69) in an open, randomized study. Bronchitis-related costs and treatment efficacy were assessed at day 5-6 and day 14-21. Both antibiotics were of equal clinical efficacy, although the median time to improvement of symptoms was significantly shorter for azithromycin patients than for clarithromycin patients. Some 77% of azithromycin patients and 78% of clarithromycin patients were unable to work for at least 1 day. The total time when patients were unable to work was shorter for azithromycin patients than for clarithromycin patients, but this difference did not remain significant when weekends and holidays were taken into account. Further studies are needed to assess the impact of azithromycin on time to clinical improvement, on lost working days, and on the associated costs.